KRP513
白细胞免疫球蛋白样受体亚家族A, Leukocyte immunoglobulin-like receptor subfamily A member 2 , CD85 antigen-like family member H, Immunoglobulin-like transcript 1, ILT-1, Leukocyte immunoglobulin-like receptor 7, LIR-7, CD antigen CD85h, ILT1, LIR7, Leukocyte immunoglobu
| Catalog Number | KRP513 |
| Alias | 白细胞免疫球蛋白样受体亚家族A, Leukocyte immunoglobulin-like receptor subfamily A member 2 , CD85 antigen-like family member H, Immunoglobulin-like transcript 1, ILT-1, Leukocyte immunoglobulin-like receptor 7, LIR-7, CD antigen CD85h, ILT1, LIR7, Leukocyte immunoglobu |
| Size | 20ug, 50ug, 100ug, 200ug, 1mg |
| Product Description | Human LILRA2(24-449 aa) |
| Molecular Name | LILRA2 |
| Product Introduction | 白细胞免疫球蛋白样受体亚家族A通过促进细胞粘附，调节免疫细胞的相互作用。。 |
| Molecular Weight | 70-81 kDa |
| Expression System | HEK293F Cells |
| Species | Human |
| Concentration | 联系销售经理获得最新批次的浓度 |
| Purity | ≥95% |
| SDS-PAGE |  |
| Purification | Affinity Purification |
| Uniprot ID | Q8N149-1 |
| Storage Condition | Store the product under sterile conditions after opening at -80℃ for 12 months. Store the lyophilized powder at -20℃. Avoid repeated freeze-thaw cycles. |
| Formulation | Supplied in PBS |
| Shipping Condition | This product is shipped on ice packs or dry ice. |
| Background | Part of the innate immune responses against microbial infection (PubMed:12529506, PubMed:27572839). Specifically recognizes a set of N-terminally truncated immunoglobulins that are produced via cleavage by proteases from a range of pathogenic bacteria and fungi, including L.pneumophila, M.hyorhinis, S.pneumoniae, S.aureus and C.albicans (PubMed:27572839). Recognizes epitopes that are in part in the variable region of the immunoglobulin light chains, but requires also the constant region for signaling (PubMed:27572839). Binds to a subset of cleaved IgM, IgG3 and IgG4 molecules, but does not bind cleaved IgA1 (PubMed:27572839). Binding of N-terminally truncated immunoglobulins mediates activation of neutrophils (PubMed:27572839). In monocytes, activation leads to the release of CSF2, CF3, IL6, CXCL8 and CCL3 and down-regulates responses to bacterial lipopolysaccharide (LPS), possibly via down-regulation of TLR4 expression and reduced signaling via TLR4 (PubMed:22479404). In eosinophils, activation by ligand binding leads to the release of RNASE2, IL4 and leukotriene C4 (PubMed:12529506). Does not bind class I MHC antigens (PubMed:19230061). {ECO:0000269|PubMed:12529506, ECO:0000269|PubMed:19230061, ECO:0000269|PubMed:22479404, ECO:0000269|PubMed:27572839}. |
| Endotoxin | < 0.1 EU per ug |
| Biological Activity | Measured by its binding ability in a functional ELISA. When Recombinant Human LILRA2/CD85h/ILT1 is coated at 2 µg/mL, Recombinant Human Angiopoietin-like Protein 7/ANGPTL7. binds with a typical ED50 of 150-900 ng/mL. |
| Product Declaration | 该产品仅供科研使用，不可直接用于人体或注射。 |
销售微信
官方公众号
0
